布地奈德福莫特罗对胸闷变异性哮喘患者FeNO影响的临床研究

Effect of Budesonide Formoterol on Exhaled Nitricoxide in Chest Tightness Variant Asthma Patients

目的观察布地奈德福莫特罗对胸闷变异性哮喘患者FeNO的影响。方法收集2016年1月~2016年12月于潍坊市人民医院呼吸内科门诊确诊的60例胸闷变异性哮喘患者,所有患者均规律吸入布地奈德福莫特罗治疗,分别于治疗后第1个月、第3个月、第6个月实施复诊,监测呼出气一氧化氮及肺功能的第1秒用力呼气容积/用力肺活量(FEV_1/FVC)指标,对患者病情实施评价,同时选择同时期到院实施健康体检的60例健康者作为对照组,测定呼出气一氧化氮及肺功能,观察研究组治疗前后患者呼出气一氧化氮和肺功能的变化,同时和对照组健康者进行比较分析。结果研究组FeNO水平显著高于健康对照组。而FEV_1/FVC要低于对照组,随着治疗的进行,不断接近对照组。经布地奈德福莫特罗吸入治疗6个月后气道反应性逐渐下降。FeNO水平显著降低,FEV_1/FVC比值升高。结论布地奈德福莫特罗能够改善胸闷变异性哮喘患者的病情,降低患者FeNO水平,升高FEV_1/FVC比值,改善气道炎症,增强肺功能。

Objective To research the effect of Budesonide Formoterol on exhaled nitricoxide in chest tightness variant asthma patients.Methods Sixty cases of patients with chest tightness variant asthma diagnosed in weifang people＇s hospital from January 2016 to December 2016 were collected,all patients were regular inhaled Budesonide Formoterol,respectively,in the first month after treatment,3months,6 months follow-up,monitoring of exhaled nitricoxide and pulmonary function of forced expiratory volume in 1 second/forced vital capacity（FEV1/FVC） index,the patient condition evaluation implementation,both at the same time to the implementation of physical examination of 60 cases of healthy subjects as control group.The patients＇ exhaled nitricoxide and pulmonary function after the treatment of Budesonide Formoterol were obeserved,and compared with the control group at the same time.Results The team FeNO were significantly higher than that of healthy controls.And FEV1/FVC was lower than the control group,as time went on,and more and more close to the control group.The airway reactivity decreased significantly after 6 months by Budesonide Formoterol inhalation therapy.FeNO were significantly reduced,FEV1/FVC ratio increased.Conclusion Budesonide Formoterol can improve the patients who suffer from chest tightness vriant asthma condition,reduce the patients＇ FeNO level,increase FEV1/FVC ratio,improve the airway inflammation,and strengthen the lung function.